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BenzimidazoleAbstract In the present study o-phenylenediamine and naphtene-1-acetic acid/2-naphthoxyacetic
acid were used as a starting material through a series of steps and 2-(naphthalen-1-ylmethyl/Naph-
thalen-2-yloxymethyl)-1H-benzimidazol-1-yl]acetohydrazide 5a, 5b were obtained. In the ﬁrst series
1,3,4-oxadiazole derivatives have been synthesized from Schiff base of the corresponding hydrazide
i.e. 2-[2-(naphthalen-1-ylmethyl)-1H-benzimidazol-1-yl]acetohydrazide 5a by using Chloramin-T.
In the second series 1,3,4-oxadiazole has been synthesized from 2-{2-[(naphthalen-2-yloxy)-
methyl]-1Hbenzimidazol-1-yl}acetohydrazide 5b by using phosphorous oxychloride and aromatic
acid. These compounds were evaluated by IR, NMR, Mass spectrometry, elemental analysis and
ﬁnally in vitro anticancer evaluation was carried out by NCI 60 Cell screen at a single high dose
(10–5 M) on various panel/cell lines. One compound 7c was found to be the most active on breast
cancer cell line and compounds 4b and 7d were moderately active.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Cancer is a group of various diseases and medically known as
malignant neoplasm, involving unregulated cell growth. It is a
major health problem in developing as well as undeveloped
countries (Abdel-Aziz, 2007; Choo et al., 2002; Al-Rasood
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search for new, safer and efﬁcient anticancer agents, aiming
the prevention or the cure of this illness. Research laboratories
are still involved deeply for the research of a new anticancer
drug. Product development involves application of existing
products to meet the therapeutic need in addition to the dis-
covery of new drugs. Literature review revealed that many
compounds bearing a ﬁve membered heterocyclic ring contain-
ing nitrogen and oxygen like oxadiazole have been synthesized
and showed a variety of biological activities like anticancer
(Sengupta et al., 2008; Jin et al., 2006; Holla et al., 2005), anti-
convulsant (Almasirad et al., 2004; Aziz et al., 2009), antimi-
crobial (Shetgiri and Nayak, 2005; Manjunatha et al., 2010;
Shailaja et al., 2010; Mulwad and Chaskar, 2006; Ansari and
Lal, 2009), anti-inﬂammatory analgesic (Bhandari et al.,
2008; Dewangan et al., 2010; Amir et al., 2007; Kumar et al.,
2008; Jayashankar et al., 2009), dyes and pigments (ShuiLv
et al., 2010), ulcerogenic (Gilani et al., 2010), antitubercular
(Ali and Shaharyar, 2007) etc.
2. Experimental
2.1. Instrumentation
The chemicals used for experimental work were commercially
procured from various chemical units viz E. Merck India Ltd.,
CDH and S.D. Fine chem. and Qualigens. These solvents and
reagents were of LR grade and puriﬁed before use. The silica
gel G (160–120 mesh) used for analytical chromatography
(TLC) was obtained from E. Merck India Ltd. Two solvent
systems were used Benzene:Acetone (9:1) and (8:2), Tolu-
ene:Ethyl Acetate:Formic acid (5:4:1). Ashless Whattman
No. 1 ﬁlter paper was used for vacuum ﬁltration. Melting
points were determined in an open glass capillary using melting
point apparatus and are uncorrected. The Proton Magnetic
Resonance spectra (1HNMR) were recorded on a Bruker
300 MHz instrument in DMSO-d6/CDCl3 using tetramethyl-
silane [(CH3)4Si] as internal standard. The Infrared spectra
of compound were recorded in KBr on Perkin-Elmer FTIR
Spectrometer and iodine Chamber and UV-lamp were used
for visualization of TLC spots. The commercially available
grades of solvents and reagents were found to be of adequate
purity. However, the presence of undesirable impurities and
others were likely to be used for experimental work was puri-
ﬁed/dried.2.1.1. Procedure for the synthesis of 2-naphthalen-1-yl/
naphthoxy-methyl-1H-benzimidazole (3a, 3b)
A mixture of o-phenylenediamine 1 (0.05 mol; 5.40 g) and
naphthylacetic acid/naphthoxyacetic acid 2 (0.05 mol) was re-
ﬂuxed in 4N HCl for 4 h on a heating mantle. After completion
of reaction, the solution was poured onto crushed ice, ammo-
nia solution was added drop wise to neutralize and the result-
ing solid was ﬁltered, washed with cold water, dried and
recrystallized with ethanol (see Scheme 1).2.1.1.1. Synthesis of 2-(naphthalen-1-ylmethyl)-1H-benzimid-
azole (3a). Yield 85%, m.p. 125–126 C, IR (KBr) cm1: 1528
(C‚N), 3302 (N-H): 1H-NMR (DMSO-d6) d ppm: 4.62 (s,
2H, CH2), 7.06–8.19 (m, 11H, aromatic), 12.37 (s, 1H, NH).EI-MS 274 (M+); Anal. Calcd. for C18H14N2C, 83.69; H,
5.46; N, 10.84. Found: C, 83.67; H, 5.49; N, 10.82.
2.1.1.2. Synthesis of 2-[(naphthalen-2-yloxy)methyl]-1H-benz-
imidazole (3b). Yield 84%, m.p. 205–207 C, IR (KBr) cm1:
1226 (C–O), 1464 (C‚N), 3297 (N–H), 3010 (CH, aromatic):
1H-NMR (DMSO-d6) d ppm: 5.34 (s, 2H, CH2O), 7.26–7.70
(m, 11H, aromatic); EI-MS 258 (M+); Anal. Calcd. for
C18H14N2O C, 78.81; H, 5.14; N, 10.21; O, 5.83 Found: C,
78.84; H, 5.15; N, 10.25; O, 5.80.
2.1.2. Synthesis of ethyl [2-(naphthalen-1-yl/naphthalen-2-
yloxymethyl)-1H-benzimidazol-1-yl]acetate (4a, 4b)
To a suspension of 2-(naphthylmethyl)-1H-benzimidazole 3
(0.01 mol), anhydrous potassium carbonate (2 g) in dry ace-
tone, ethyl chloroacetate (0.01 mol; 1.2 ml) was added drop
wise at room temperature for a period of 20–30 min. The reac-
tion mixture was stirred at room temperature for 10–12 h. The
inorganic solid was ﬁltered off and the ﬁltrate was concen-
trated under reduced pressure.
2.1.2.1. Synthesis of ethyl [2-(naphthalen-1-ylmethyl)-1H-ben-
zimidazol-1-yl]acetate (4a). Yield 72%, m.p. 108–112 C, IR
(KBr) cm1: 1229 (C–O), 1436 (C‚N), 3206 (N–H), 3010
(CH, aromatic); 1H-NMR (DMSO-d6) d ppm: 4.14 (s, 2H,
CH2 naphthyl), 5.06 (s, 2H, CH2) 7.46–7.79 (m, 11H, aromatic);
EI-MS 360 (M+); Anal. Calcd. for C22H20N2O2, C, 76.72; H,
5.85; N, 8.13; O, 9.29. Found: C, 76.70;H, 5.88; N, 8.12; O, 9.29.
2.1.2.2. Synthesis of ethyl {2-[(naphthalen-2-yloxy)methyl]-
1H-benzimidazol-1-yl}acetate (4b). Yield 69%, m.p. 105–
109 C, IR (KBr) cm1: 1226 (C–O), 1464 (C‚N), 1736
(C‚O), 2950 (CH, aromatic); 1H-NMR (DMSO-d6) d ppm:
4.72 (s, 2H, CH2), 5.21 (s, 2H, CH2O) 6.90–7.61 (m, 11H, aro-
matic); EI-MS 344 (M+); Anal. Calcd. for C22H20N2O3C,
73.32; H, 5.59; N, 7.77; O, 13.32. Found: C, 73.29; H, 5.60;
N, 7.80; O, 13.35.
2.1.3. Synthesis of 2-[2-(naphthalen-1-yl/naphthalen-2-yloxy
methyl)-1H-benzimidazol-1-yl]acetohydrazide (5a, 5b)
To an ethanolic solution of ethyl [2-(naphthalen-1-ylmethyl)/
(naphthalen-2-yloxy)methyl]-1H-benzimidazol-1-yl]acetate 4a,
4b (0.01 mol), hydrazine hydrate (98%) (0.01 mol; 0.49 ml)
was added and the mixture was reﬂuxed for 3 h. After comple-
tion of the reaction, the mixture was cooled and the solid so
obtained was ﬁltered, washed with cold water and recrystal-
lized from methanol.
2.1.3.1. Synthesis of 2-[2-(naphthalen-1-ylmethyl)-1H-ben-
zimidazol-1-yl]acetohydrazide (5a). Yield 82% mp. 147–
150 C, IR (KBr) cm1: 1233 (N–N), 1528 (C‚N); 1643
(C‚O), 3043 (CH–Ar), 3302 (N–H); 1H-NMR (DMSO-d6)
d ppm: 2.50 (s, 1H, NH2), 4.90 (s, 2H, CH2), 7.13–8.15 (m,
11H, aromatic), 9.25 (s, 1H, CONH); EI-MS 346 (M+); Anal.
Calcd. for: C22H18N4OC, 72.71; H, 5.49, N, 16.96; O, 4.84
Found: C, 72.71; H, 5.50, N, 16.94; O, 4.82.
2.1.3.2. Synthesis of 2-{2-[(naphthalen-2-yloxy)methyl]-1H-
benzimidazol-1-yl}acetohydrazide (5b). Yield 82% mp. 208–
210 C, IR (KBr) cm1: 1254 (N–O), 1466 (C‚N); 1668
(C‚O), 3056 (CH–Ar), 3292 (N–H); 1H-NMR (DMSO-d6) d
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420 Salahuddin et al.ppm: 2.53 (s, 1H, NH2), 4.89 (s, 2H, CH2), 5.35 (s, 1H, CH2O),
6.92–7.70 (m, 11H, aroamtic), 9.05 (s, 1H, CONH); EI-MS 330
(M+); Anal. Calcd. for: C22H18N4O2C, 69.35; H, 5.24; N, 16.17;
O, 9.24 Found: C, 69.30; H, 5.21; N, 16.21; O, 9.27.
2.1.4. Synthesis of 2-[2-(naphthylmethyl)-1H-benzimidazol-1-
yl]-N’-[substituted phenylmethylidene] acetohydrazide (6a–f)
A mixture of 2-[2-(naphthylmethyl)-1H-benzimidazol-1-
yl]acetohydrazide 5 (0.0025 mol) and substituted benzaldehyde
(0.0025 mol) in ethyl alcohol (10 ml) and few drops of glacialacetic acid were reﬂuxed for 5 h. After completion of reaction,
the reaction mixture was concentrated, cooled, poured in ice
cold water, the precipitate so formed was ﬁltered, dried and re-
crystallized with ethanol to give desired compound.
2.1.4.1. (2-Naphthalen-1-ylmethyl-benzimidazol-1-yl)-acetic
acid benzylidene-hydrazide (6a). Yield 76%; m.p. 208–
209 C, IR (KBr) cm1: 1134 (N–N), 1594 (C‚N); 1669
(C‚O), 3045 (CH–Ar), 3193 (N–H); 1H-NMR (DMSO-d6)
d ppm: 4.08 (s, 2H, CH2 naphthyl), 4.46 (s, 2H, CH2), 7.43–
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(M+ 1)+; Anal. Calcd. for C27H22N4O: C, 77.49; H, 5.30;
N, 13.39; O, 3.82 Found: C, 77.46; H, 5.33; N, 13.41; O, 3.80.
2.1.4.2. (2-Naphthalen-1-ylmethyl-benzimidazol-1-yl)-acetic
acid (4-chloro-benzylidene)-hydrazide (6b). Yield 80%; m.p.
200–202 C, IR (KBr) cm1: 1252 (N–N), 1489 (C‚N); 1667
(C‚O), 2962 (CH–Ar), 3181 (N–H); 1H-NMR (DMSO-d6)
d ppm: 4.05 (s, 2H, CH2 naphthyl), 5.47 (s, 2H, CH2), 7.42–
8.26 (m, 15H, aroamtic), 11.51 (s, 1H, CONH); EI-MS 469
(M+ 1)+; Anal. Calcd. for C27H19ClN4O: C, 71.60; H,
4.67; Cl, 7.83; N, 12.37; O, 3.53 Found: C, 71.60; H, 4.65;
Cl, 7.82; N, 12.38; O, 3.52.
2.1.4.3. (2-Naphthalen-1-ylmethyl-benzimidazol-1-yl)-acetic
acid (4-nitro-benzylidene)-hydrazide (6c). Yield 78%; m.p.
226–227 C, IR (KBr) cm1: 1520 (N‚C); 1662 (C‚O);
3042 (CH–Ar); 3176 (N–H); 1H-NMR (DMSO-d6) d ppm:
3.99 (s, 2H, CH2 naphthyl), 4.41 (s, 2H, CH2), 6.95–8.15 (m,
15H, aroamtic), 11.35 (s, 1H, CONH); EI-MS 478 (M+); Anal.
Calcd. for C27H21N5O3: C, 69.97; H, 4.57; N, 15.11; O, 10.36.
Found: C, 69.95; H, 4.60; N, 15.10; O, 10.39.
2.1.4.4. (2-Naphthalen-1-ylmethyl-benzimidazol-1-yl)-acetic
acid (4-methoxy-benzylidene)-hydrazide (6d). Yield 75%;
m.p. 186–187 C, IR (KBr) cm1: 1512 (N‚C); 1661
(C‚O); 3051 (CH–Ar); 3202 (N–H); 1H-NMR (DMSO-d6)
d ppm: 3.98 (s, 2H, CH2 naphthyl), 4.40 (s, 2H, CH2), 6.69–
8.12 (m, 15H, aroamtic), 11.18 (s, 1H, CONH); EI-MS 465
(M+ 1)+; Anal. Calcd. for C28H24N4O2: C, 74.98; H, 5.39;
N, 12.49; O, 7.13. Found: C, 74.98; H, 5.39; N, 12.49; O, 7.13.
2.1.4.5. (2-Naphthalen-1-ylmethyl-benzimidazol-1-yl)-acetic
acid (4-dimethylamino-benzylidene)-hydrazide (6e). Yield
82%; m.p. 289–290 C, IR (KBr) cm1: 1496 (N‚C); 1654
(C‚O); 3041 (CH–Ar); 3194 (N–H); 1H-NMR (DMSO-d6)
d ppm: 3.30 (s, 3H, CH3), 4.05 (s, 2H, CH2 naphthyl), 4.47
(s, 2H, CH2), 7.43–8.25 (m, 15H, aroamtic), 11.58 (s, 1H,
CONH); EI-MS 478 (M+ 1); Anal. Calcd. for C29H27N5O:
C, 75.47; H, 5.91; N, 15.19; O, 3.50. Found: C, 75.43; H,
5.89; N, 15.14; O, 3.49.
2.1.4.6. (2-Naphthalen-1-ylmethyl-benzimidazol-1-yl)-acetic
acid (2-hydroxy-benzylidene)-hydrazide (6f). Yield 82%; m.p.
289–290 C, IR (KBr) cm1: 1466 (N‚C); 1739 (C‚O); 3048
(CH–Ar); 3294 (N–H); 1H-NMR (DMSO-d6) d ppm: 4.04 (s,
2H,CH2naphthyl), 4.46 (s, 2H,CH2), 6.98–8.21 (m, 15H, aroam-
tic), 10.18 (s, 1H, CONH), 11.39 (s, 1H, OH); EI-MS 451
(M+ 1)+; Anal. Calcd. for C27H22N4O2: C, 74.64; H, 5.10; N,
12.89; O, 7.36. Found: C, 74.62; H, 5.13; N, 12.90; O, 7.39.
2.1.5. General procedure for the synthesis of 2-Naphthalen-1-
ylmethyl-1-(5-substituted phenyl-[1,3,4]oxadiazol-2-ylmethyl)-
1H-benzimidazole (7a–f)
To an ethanolic solution of 2-[2-(Naphthylmethyl)-1H-ben-
zimidazol-1-yl]-N’-[phenylmethylidene] acetohydrazide (0.0025
mol), chloramin T (0.0125 mol) was added. The solution was re-
ﬂuxed for 4 h, sodium chloride which separated out during the
course of reaction was ﬁltered off. Excess ethanol was com-
pletely removed from the ﬁltrate by distillation under reduced
pressure, leaving behind a solid mass which was crystallized
from ethanol to give desired compound.2.1.5.1. 2-Naphthalen-1-ylmethyl-1-(5-phenyl-[1,3,4]oxadiazol-
2-ylmethyl)-1H-benzimidazole (7a). Yield 65%; m.p. 172–
174 C, IR (KBr) cm1: 1034 (N–N); 1231 (C–O); 1598
(C‚N); 2963 (CH–Ar); 1H-NMR (DMSO-d6) d ppm: 5.33
(s, 2H, CH2 naphthyl), 5.55 (s, 2H, CH2), 7.16–7.86 (m,
16H, aromatic); EI-MS 431 (M+); Anal. Calcd. for
C27H20N4O: C, 77.87; H, 4.84; N, 13.45; O, 3.84. Found: C,
77.85; H, 4.85; N, 13.43; O, 3.80.
2.1.5.2. 1-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-
2-naphthalen-1-ylmethyl-1H-benzimidazole (7b). Yield 71%;
m.p. 221–223 C, IR (KBr) cm1: 773 (C–Cl); 1085 (N–N);
1228 (C–O); 1489 (C‚N); 2962 (CH–Ar); 1H-NMR
(DMSO-d6) d ppm: 4.70 (s, 2H, CH2 naphthyl), 5.24 (s, 2H,
CH2), 7.13–8.21 (m, 15H, aromatic); EI-MS 467 (M+ 1)
+;
Anal. Calcd. for C27H19ClN4O: C, 71.92; H, 4.25; Cl, 7.86;
N, 12.43; O, 3.55. Found: C, 71.92; H, 4.25; Cl, 7.83; N,
12.45; O, 3.51.
2.1.5.3. 2-Naphthalen-1-ylmethyl-1-[5-(4-nitro-phenyl)-[1,3,4]
oxadiazol-2-ylmethyl]-1H-benzimidazole (7c). Yield 71%;
m.p. 245–246 C, IR (KBr) cm1: 1070 (N–N); 1232 (C–O);
1519 (C‚N); 3041 (CH–Ar); 1H-NMR (DMSO-d6) d ppm:
5.41 (s, 2H, CH2 naphthyl), 5.65 (s, 2H, CH2), 7.09–7.85 (m,
15H, aromatic); EI-MS 477 (M+); Anal. Calcd. for
C27H20N5O3: C, 70.27; H, 4.15; N, 15.18; O, 10.40. Found:
C, 70.25; H, 4.17; N, 15.17; O, 10.40.
2.1.5.4. 1-[5-(4-Methoxy-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-
2-naphthalen-1-ylmethyl-1H-benzimidazole (7d). Yield 82%;
m.p. 170–172 C, IR (KBr) cm1: 1168 (N–N); 1257 (C–O);
1508 (C‚N); 3041 (CH–Ar); 1H-NMR (DMSO-d6) d ppm:
2.46 (s, 3H, CH3), 4.05 (s, 2H, CH2 naphthyl), 4.42 (s, 2H,
CH2), 7.35–8.93 (m, 15H, aromatic); EI-MS 463 (M+ 1)
+;
Anal. Calcd. for C28H22N4O2: C, 75.32; H, 4.97; N, 12.55; O,
7.17. Found: C, 75.31; H, 4.97; N, 12.54; O, 7.18.
2.1.5.5. Dimethyl-{4-[5-(2-naphthalen-1-ylmethyl-benzimidazol-1-
ylmethyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-amine (7e). Yield
71%; m.p. 187–190 C, IR (KBr) cm1: 1139 (N–N); 1234
(C–O); 1531 (C‚N); 2857 (CH–Ar); 1H-NMR (DMSO-d6) d
ppm: 2.50 (s, 6H, CH3), 3.97 (s, 2H, CH2 naphthyl), 4.48 (s,
2H, CH2), 7.16–8.27 (m, 15H, aromatic); EI-MS 344
(M+ 1)+; Anal. Calcd. for C29H25N5O: C, 75.80; H, 5.48;
N, 15.24, O, 3.48. Found: C, 75.82; H, 5.48; N, 15.21, O, 3.45.
2.1.5.6. 2-[5-(2-Naphthalen-1-ylmethyl-benzimidazol-1-ylmethyl)-
[1,3,4]oxadiazol-2-yl]-phenol (7f). Yield 74%; m.p. 102–
104 C, IR (KBr) cm1: 1027 (N–N); 1216 (C–O); 1503
(C‚N); 2979 (CH–Ar); 1H-NMR (DMSO-d6) d ppm: 4.01
(s, 2H, CH2 naphthyl), 4.40 (s, 2H, CH2), 7.30–8.11 (m,
15H, aromatic), 9.82 (s, 1H, OH); EI-MS 449 (M+ 1)+; Anal.
Calcd. for C27H20N4O2: C, 74.98; H, 4.66; N, 12.95; O, 7.40.
Found: C, 74.98; H, 4.66; N, 12.95; O, 7.40.
2.1.6. Synthesis of 2-(Naphthalen-2-yloxymethyl)-1-(5-
substituted phenyl-[1,3,4]oxadiazol-2-ylmethyl)-1H-
benzimidazole (8a–e)
A mixture of 2-{2-[(naphthalen-2-yloxy)methyl]-1H-ben-
zimidazol-1-yl}acetohydrazide 5b (0.0025 mol) and suitable
aromatic acid (0.0025 mol) was reﬂuxed in the presence of
422 Salahuddin et al.POCl3 (5 ml) for 5 h at a temperature of 110–120 C. After
completion of reaction, the mixture was cooled at room tem-
perature and poured onto crushed ice. On basiﬁcation with so-
dium bicarbonate (5%), a solid mass separated out was ﬁltered
to get crude product. Finally the product was heated with
charcoal in hydrated ethanol and then re-crystallized from eth-
anol to obtain 8a–e.
2.1.6.1. Synthesis of 2-(Naphthalen-2-yloxymethyl)-1-(5-phe-
nyl-[1,3,4]oxadiazol-2-ylmethyl)-1H-benzimidazole (8a).
Yield 67% m.p. 204–208 C IR (KBr) cm1: 1031 (N–N),
1250 (C–O), 1605 (C‚N); 1H-NMR (DMSO-d6) d ppm:
4.67 (s, 2H, CH2), 5.64 (s, 2H, OCH2), 7.09–7.76 (m, 16H, aro-
matic); EI-MS 416 (M+); Anal. Calcd. for C27H20N4O2: C,
74.98; H, 4.66; N, 12.95; O, 7.40 Found: C, 74.95; H, 4.69;
N, 12.93; O, 7.45.
2.1.6.2. Synthesis of 1-[5-(2-Chloro-phenyl)-[1,3,4]oxadiazol-
2-ylmethyl]-2-(naphthalen-2-yloxymethyl)-1H-benzimidazole
(8b). Yield 63%; m.p. 108–110 C, IR (KBr) cm1: 740 (C–
Cl); 1028 (N–N), 1238 (C–O), 1583 (C‚N), 3026 (CH–Ar);
1H-NMR (DMSO-d6) d ppm: 4.45 (s, 2H, CH2), 5.03 (s, 2H,
OCH2), 6.73–7.79 (m, 15H, aroamtic), EI-MS 451
(M+ 1)+. Anal. Calcd. for C27H19CIN4O2: C, 69.45; H,
4.10;Cl, 7.59; N, 12.00; O, 6.85 Found: C, 69.41; H, 4.14; Cl,
7.61; N, 11.97; O, 6.83.Table 1 Anticancer screening data of title compounds.
Compound 60 cell lines assay in 1 dose 10–5 M conc.
NSC code Mean
growth %
Range of
growth %
Th
cel
3b 764,708 89.44 61.59–123.30 A-
HO
4b 764,709 79.28 47.08–97.79 NC
UO
6d 764,703 95.73 69.53–109.35 MO
UO
6f 764,706 94.99 63.19–108.33 UO
UA
7a 764,700 84.91 25.17–110.90 HO
UO
7b 764,701 91.53 51.36–107.82 SN
NC
7c 764,702 72.85 36.23–101.81 MD
SK
7d 764,704 74.09 32.73–100.64 NC
UO
7e 764,705 95.10 64.10–109.28 UO
HO
7f 764,707 96.59 62.97–111.45 UO
HO
8a 764,710 92.20 56.74–111.52 UO
MO
8b 764,711 80.54 40.96–111.19 UO
MO
8c 764,712 101.87 71.70–118.83 UO
HO
8d 764,713 96.10 54.01–110.84 UO
HO
8e 764,714 92.62 47.35–108.14 UO
PC2.1.6.3. Synthesis of 2-{5-[2-(Naphthalen-2-yloxymethyl)-ben-
zoimidazol-1-ylmethyl]-[1,3,4]oxadiazol-2-yl}-phenylamine
(8c). Yield 66%; m.p. 220–222 C, IR (KBr) cm1: 1037 (N–
N), 1246 (C–O), 1598 (C‚N), 3067 (CH–Ar); 1H-NMR
(DMSO-d6) d ppm: 4.0 (s, 2H, NH2), 4.91 (s, 2H, CH2), 5.31
(s, 2H, OCH2), 6.73–7.79 (m, 15H, aroamtic), EI-MS 432
(M+ 1)+. Anal. Calcd. for C27H21N5O2: C, 72.47; H, 4.73;
N, 15.65; O, 7.15 Found: C, 72.45; H, 4.77; N, 15.67; O, 7.13.
2.1.6.4. Synthesis of 2-(Naphthalen-2-yloxymethyl)-1-[5-(4-
nitro-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1H-benzimidazole
(8d). Yield 69%; m.p. 80-84 C, IR (KBr) cm1: 1035 (N–N);
1239 (C–O); 1568 (NO2); 1685 (C‚N); 3032 (CH–Ar);
1H-
NMR (DMSO-d6) d ppm: 4.50 (s, 2H, CH2), 5.28 (s, 2H,
OCH2), 6.91–7.71 (m, 15H, aromatic); EI-MS 461 (M
+); Anal.
Calcd. for C27H19N5O4: C, 67.92; H, 4.01; N, 14.67; O, 13.40
Found: 67.89; H, 4.05; N, 14.70; O, 13.37.
2.1.6.5. Synthesis of 12-(Naphthalen-2-yloxymethyl)-1-[5-(3,5-
dinitro-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1H-benzimid-
azole (8e). Yield 74%; m.p. 155-157 C, IR (KBr) cm1: 1035
(N–N); 1239 (C–O); 1566 and 1350 (NO2); 1685 (C‚N); 3063
(CH–Ar); 1H-NMR (DMSO-d6) d ppm: 5.12 (s, 2H, CH2), 5.37
(s, 2H, OCH2), 6.91–7.78 (m, 14H, aroamtic), EI-MS 507
(M+ 1)+; Anal. Calcd. for C27H18N6O6: C, 62.07; H, 3.47;
N, 16.09; O, 18.37 Found: C, 62.12; H, 3.44; N, 16.11; O, 18.35.e most sensitive
l line
Growth % of the most
sensitive cell line
498 (renal cancer) 61.59
P-92 (non-small cell lung cancer) 63.30
I-H522 (Non-small Cell Lung Cancer) 47.08
-31 (renal cancer) 57.33
LT-4 (leukemia) 69.53
-31 (renal cancer) 72.14
-31 (renal cancer) 63.19
CC-62 (melanoma) 74.16
P-92 (non-small cell lung cancer) 25.17
-31 (renal cancer) 63.88
B-75 (CNS cancer) 51.36
I-H522 (non-small cell lung cancer) 72.21
A-MB-468 (Breast Cancer) 36.23
-MEL-28 (melanoma) 47.56
I-H522 (non-small cell lung cancer) 32.73
-31 (renal cancer) 40.53
-31 (renal cancer) 64.10
P-92 (non-small cell lung cancer) 70.12
-31 (renal cancer) 62.97
P-92 (non-small cell lung cancer) 78.32
-31 (renal cancer) 56.74
LT-4 (leukemia) 72.02
-31 (renal cancer) 40.96
LT-4 (leukemia) 41.37
-31 (renal cancer) 71.70
P-92 (non-small cell lung cancer) 74.53
-31 (renal cancer) 54.01
P-92 (non-small cell lung cancer) 76.98
-31 (renal cancer) 47.35
-3 (prostate cancer) 69.80
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2.2.1. Treatment of tumor cell lines
All compounds submitted to the NCI 60 Cell screen were tested
initially at a single high dose (105 M) on leukemia, melanoma,
lung, colon, CNS, ovarian, renal, prostate, and breast cancer
cell lines, nearly 60 in number. The one-dose data were reported
as a mean graph of the percent growth of treated cells. The
number reported for the one-dose assay is growth relative to
the no-drug control, and relative to the time zero number of
cells. The anticancer screening was carried out as per the NCI
US protocol reported elsewhere (http://dtp.nci.nih.gov; Turn-
er, 1964; Monks et al., 1991; Boyd and Paull, 1995; Shoemaker,
2006). Using the seven absorbance measurements [time zero,
(Tz), control growth, (C), and test growth in the presence of
drug at the ﬁve concentration levels (Ti)], the percentage
growth was calculated at each of the drug concentration levels.
Percentage growth inhibition is calculated as:
½ðTiTzÞ=ðCTzÞ  100 for concentrations for which Ti>=¼Tz
½ðTiTzÞ=Tz  100 for concentrations for which Ti<Tz:
3. Result and discussion
3.1. Chemistry
2-Naphthalen-1-yl/naphthoxy-methyl-1H-benzimidazole 3a,
3b were prepared by reﬂuxing with o-phenylenediamine 1
and naphthalene-1-acetic acid/2-naphthoxyacetic acid 2 in
the presence of 4NHCl. The compounds 3a, 3b on reacting
with ethylchloroacetate in the presence of potassium carbonate
in dry acetone gave ethyl [2-(naphthalen-1-yl/naphthalen-2-yl-
oxymethyl)-1H-benzimidazol-1-yl]acetate 4a, 4b which on
treatment with hydrazine hydrate result in the formation of
2-[2-(naphthalen-1-ylmethyl/naphthalen-2-yloxymethyl)-1H-
benzimidazol-1-yl]acetohydrazide 5a, 5b. The compound 5a on
treatment with aromatic aldehyde and alcohol gave Sciff base
which is (2-Naphthalen-1-ylmethyl-benzoimidazol-1-yl)-acetic
acid substituted benzylidene-hydrazide 6a–f. Sciff base 6a–f
on reacting with ethyl alcohol and Chloramin-T gives 2-Naph-
thalen-1-ylmethyl-1-(5-substitutedphenyl-[1,3,4]oxadiazol-2-
ylmethyl)-1H-benzimidazole 7a–f. Finally the compound 5b on
treating with various aromatic acids and phosphorous oxy-
chloride gave 2-(Naphthalen-2-yloxymethyl)-1-(5-substituted
phenyl-[1,3,4]oxadiazol-2-ylmethyl)-1H-benzimidazole 8a–d.
3.2. Anticancer activity
The synthesized title compounds displayed moderate to low
activity in the in vitro screen on all tested cancer cell lines
and are given in Table 1. The compound 7c was found to be
the most active compound of the series that showed 72.85
growth percent (GP) and highly active on MDA-MB-468
(Breast cancer) and SK-MEL-28 (Melanoma) (GP = 36.23
and 47.56, respectively). The compounds 7d and 4b showing
moderate activity were highly active on NCI-H522 (Non-small
cell lung cancer) with GP of 32.73 and 47.08, respectively and
on UO-31 (Renal cancer) with 40.53 and 57.33, respectively,
while rest of the compounds showed less activity with an aver-
age growth percent of 84.91–96.59.4. Conclusion
A novel 2-Naphthalen-1-ylmethyl-1-(5-substituted phenyl-[1,3,4]
oxadiazol-2-ylmethyl)-1H-benzimidazole (7a–f) and 2-(Naph-
thalen-2-yloxymethyl)-1-(5-phenyl-[1,3,4]oxadiazol-2-ylmethyl)-
1H-benzimidazole (8a–e) have been synthesized by using
chloramin-T from Schiff base and phosphrous oxychloride
from hydrazides. The in vitro anticancer studies reveal that
the compound with para substituent like p-NO2 (7c) showed
a prominent activity against MDA-MB-468 (Breast cancer)
and SK-MEL-28 (Melanoma) (GP = 36.23 and 47.56, respec-
tively) probably because of more electron withdrawing power
of the other substituents. While the other compounds 7d and
4b showed moderate activity against selected cancer cell line.
Thus the study revealed that these compounds have potential
anticancer activity and structural modiﬁcation may lead to
the synthesis of more 1,3,4-oxadiazole derivatives and can be
evaluated for their anticancer activities in vitro as well as
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